Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University

Director, Sarcoidosis Program, Temple University Hospital

 and pulmonary hypertension remain the strongest markers of poor outcomes in pulmonary sarcoidosis, but current data do not yet support routine antifibrotic therapy in fibrotic disease, according to Rohit Gupta, MD, professor of thoracic medicine and surgery at the Lewis Katz School of Medicine at Temple University and director of the sarcoidosis program at Temple University Hospital.

Gupta spoke with HCPLive after a sarcoidosis management session at the 

, held October 18-21, 2026, in Phoenix, Arizona. He said advanced pulmonary sarcoidosis, marked by extensive fibrosis, sarcoidosis-associated pulmonary hypertension (SAPH), respiratory failure, or oxygen need, carries higher morbidity and mortality. Prognostic tools such as the Walsh and modified Walsh models combine pulmonary function and CT findings to identify patients at risk of poor outcomes.

Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD

"We really do not know the trajectory of these patients who have fibrotic pulmonary sarcoidosis. Some of them are very stable and they do not die because of the fibrotic disease, but some would, and we do not know who are those patients at this time," Gupta said.

Progressive pulmonary fibrosis trials enrolled few patients with sarcoidosis, Gupta said, and some patients with fibrotic disease still have active inflammation which may respond to 

anti-inflammatory therapy with gains in forced vital capacity (FVC)

. He said antifibrotics may suit select patients with progression and no inflammatory activity, decided case by case.

Assessing disease activity remains difficult, Gupta said, noting serum angiotensin-converting enzyme has poor sensitivity and specificity, while soluble IL-2 receptor, C-reactive protein, and CT findings such as ground-glass opacities can help, with PET-CT used less often. For SAPH, he noted only 2 double-blind, placebo-controlled trials exist and called for dedicated multicenter trials, though carefully selected patients with precapillary disease can improve with treatment.

The session also covered the PREDMETH trial, in which methotrexate was noninferior to prednisone for change in percent-predicted FVC at 24 weeks as first-line therapy in 138 treatment-naive patients with pulmonary sarcoidosis (adjusted difference, −1.17 percentage points; 95% CI, −4.27 to 1.93).

 Gupta said methotrexate takes longer to improve symptoms and FVC but could serve as a first-line option, in line with efforts to limit cumulative steroid exposure.

Walsh SLF, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. 

Kahlmann V, Janssen Bonás M, Moor CC, et al. First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate. 

. 2025;393(3):231-242. doi:10.1056/NEJMoa2501443

Videos

Rohit Gupta, MD, discusses advanced pulmonary sarcoidosis, antifibrotic uncertainty, and first-line methotrexate data after a CHEST 2026 session.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Pulmonary Fibrosis

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The US Food and Drug Administration (FDA) has granted accelerated approval to doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP), making it the first plasmid DNA-based immunotherapy approved in the US.

Parent company Inovio announced the approval on October 30, 2026. It is based on complete response data from the open-label, multicenter RRP-001 trial.

"The approval of VOCERYQ is an important step in improving the quality of life for RRP patients as every surgery carries the risk of laryngeal injury,” said Simon Best, Associate Professor of Otolaryngology at Johns Hopkins University and a lead investigator for Inovio’s RRP-001 study. “I believe it is in the best interest of RRP patients that the standard of care quickly transition away from surgical interventions to immunotherapy after RRP is diagnosed."

The approval comes a little more than a year after the FDA approved zopapogene imadenovec-drba (Papzimeos), an adenoviral vector-based immunotherapy, for adults with RRP.

 Voceryq delivers 2 plasmids. One encodes HPV-6 and HPV-11 antigens, and the other encodes the immune-enhancing cytokine interleukin-12 (IL-12).

Voceryq is given by intramuscular injection with the CELLECTRA 5PSP device, which uses electroporation to help the DNA get into cells.

 The FDA approved the drug and device together.

What Did the RRP-001 Trial Show for Voceryq?

RRP-001 enrolled 32 adults with RRP who had at least two papilloma excision surgeries in the prior 12 months, including a surgery scheduled at trial entry.

 According to Inovio, all 32 participants completed the study.

Before the first dose, patients had standard-of-care surgical debulking of visible papillomas. A 9-week dosing regimen followed. Under the protocol, no additional excision surgeries were required during the dosing window.

The efficacy population was made up of 26 patients with 3 or more surgeries in the 12 months before enrollment. They had a median of 4.5 baseline surgeries (range, 3-8). In this group, 27% (7/26; 95% CI, 12%-48%) achieved a complete response, defined as no surgical intervention through 12 months of follow-up.

RRP-001 had no control arm. The FDA based its decision on the reduction in surgery frequency, an intermediate clinical endpoint it considers reasonably likely to predict clinical benefit.

 According to Inovio, complete responses of this kind are not expected in the untreated natural history of the disease.

“Adults living with recurrent respiratory papillomatosis often face an exhausting and relentless cycle of repeated surgeries, managing their disease, but never truly escaping it. Today’s approval represents a meaningful scientific breakthrough: a plasmid DNA-based immunotherapy that harnesses the body’s own immune system to fight the underlying cause of RRP,” said Karim Mikhail, BPharm, MS, Director of the Center for Biologics Evaluation and Research (CBER). “For patients, that could mean fewer surgeries, fewer disruptions, and more time living their lives on their own terms. The FDA is proud to help bring that possibility within reach.”

What Are the Safety Considerations With Voceryq?

The most common adverse reactions, each in more than 5% of patients, were:

Inovio reported most treatment-related reactions were grade 1 or 2 and transient. No grade 4 or 5 common adverse events occurred.

The label’s warnings and precautions include injection site reactions, and Inovio advises monitoring patients for at least 30 minutes after each treatment.¹ Per the FDA, possible effects of electroporation include:

transient changes in creatine phosphokinase

Clinicians should avoid using the device on the same side as an implanted cardioverter-defibrillator or pacemaker. They should also avoid treatment sites with metal implants or skin abnormalities.

Continued approval may depend on a confirmatory trial to verify clinical benefit. Inovio described plans to submit a draft protocol to the FDA by the end of 2026, with final protocol alignment expected by mid-2027.

Inovio expects ordering and shipping to begin about 60 days after approval, with full commercial field deployment in the first quarter of 2027. Voceryq has FDA Orphan Drug and Breakthrough Therapy designations. Under its development name, INO-3107, it also has European Commission Orphan Drug designation.

INOVIO Pharmaceuticals. INOVIO announces FDA accelerated approval of VOCERYQ, an immunotherapy to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). Published October 30, 2026. Accessed October 30, 2026. 

https://ir.inovio.com/news/news-details/2026/INOVIO-Announces-FDA-Accelerated-Approval-of-VOCERYQ-an-Immunotherapy-to-Reduce-the-Frequency-of-Surgery-in-Adults-with-Recurrent-Respiratory-Papillomatosis-RRP/default.aspx

US Food and Drug Administration. FDA approves first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis. Published October 30, 2026. Accessed October 30, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis

US Food and Drug Administration. FDA approves first immunotherapy for recurrent respiratory papillomatosis. Published August 14, 2025. Accessed October 30, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-immunotherapy-recurrent-respiratory-papillomatosis

Articles

The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.

FDA News

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

Abdallah Geara, MD, is an Associate Professor of Clinical Medicine at the University of Pennsylvania.

Welcome back to another HCPLive Peer Exchange series. In "IgAN Progression Risk: Proteinuria, eGFR Decline, and the Role of Hematuria," moderator Shikha Wadhwani, MD, MS, FASN is joined by Chee Kay Cheung, MBChB, MRCP, PhD, FHEA and Abdallah S. Geara, MD to open the series on IgA nephropathy.  Dr. Wadhwani welcomes viewers, introduces the panel, and previews the discussion before asking Dr. Geara how much risk of kidney failure remains despite recent therapeutic advances. Dr. Geara describes IgAN as a progressive chronic kidney disease that leads to dialysis in the majority of patients. He notes that the disease affects every race and ethnicity, although patients of East Asian ancestry tend to present younger with more progressive disease. Age at onset and eGFR at presentation are additional risk markers. Dr. Cheung adds that proteinuria and eGFR decline are the two key variables, with proteinuria standing out as the main modifiable risk factor. Dr. Cheung cites the recent KDIGO guidance, which targets proteinuria below 0.5 grams per day and an eGFR decline under 1 mL/min per year, matching physiologic aging.  Dr. Wadhwani recalls that a goal of less than 1 gram per day once seemed sufficient, and that registry data, including the UK RADAR registry, have changed that thinking. Dr. Cheung explains that proteinuria can be measured accurately in clinic, whereas eGFR trajectory needs many data points over a longer period, so early proteinuria response guides judgment about a new treatment. The panel then debates hematuria. Dr. Cheung considers proteinuria and eGFR decline far better validated, notes that isolated hematuria with stable function carries a good outlook, and observes that therapies can now reduce hematuria. Dr. Geara agrees that hematuria is not uniform across patients. He treats its disappearance on targeted therapy, and its return after stopping, as a sign of recurring inflammation, interpreted patient by patient.  The next episode in this series, "IgAN Treatment Escalation: Beyond Supportive Care and Access Barriers," features the panel weighing when supportive care alone falls short and what ambitious goals now look like.

IgAN Progression Risk: Proteinuria, eGFR Decline, and the Role of Hematuria

Welcome back to another HCPLive Peer Exchange series. In "IgAN Progression Risk: Proteinuria, eGFR Decline, and the Role of Hematuria," moderator Shikha Wadhwani, MD, MS, FASN is joined by Chee Kay Cheung, MBChB, MRCP, PhD, FHEA and Abdallah S. Geara, MD to open the series on IgA nephropathy.

Dr. Wadhwani welcomes viewers, introduces the panel, and previews the discussion before asking Dr. Geara how much risk of kidney failure remains despite recent therapeutic advances. Dr. Geara describes IgAN as a progressive chronic kidney disease that leads to dialysis in the majority of patients. He notes that the disease affects every race and ethnicity, although patients of East Asian ancestry tend to present younger with more progressive disease. Age at onset and eGFR at presentation are additional risk markers. Dr. Cheung adds that proteinuria and eGFR decline are the two key variables, with proteinuria standing out as the main modifiable risk factor. Dr. Cheung cites the recent KDIGO guidance, which targets proteinuria below 0.5 grams per day and an eGFR decline under 1 mL/min per year, matching physiologic aging.

Dr. Wadhwani recalls that a goal of less than 1 gram per day once seemed sufficient, and that registry data, including the UK RADAR registry, have changed that thinking. Dr. Cheung explains that proteinuria can be measured accurately in clinic, whereas eGFR trajectory needs many data points over a longer period, so early proteinuria response guides judgment about a new treatment. The panel then debates hematuria. Dr. Cheung considers proteinuria and eGFR decline far better validated, notes that isolated hematuria with stable function carries a good outlook, and observes that therapies can now reduce hematuria. Dr. Geara agrees that hematuria is not uniform across patients. He treats its disappearance on targeted therapy, and its return after stopping, as a sign of recurring inflammation, interpreted patient by patient.

"IgAN Treatment Escalation: Beyond Supportive Care and Access Barriers,"

features the panel weighing when supportive care alone falls short and what ambitious goals now look like.

Despite new therapies, IgAN still progresses to kidney failure in most patients. The panel reviews who is at greatest risk, which targets matter, and how hematuria fits alongside proteinuria and eGFR.

Marla Dubinsky, MD, is chief of the division of pediatric gastroenterology and nutrition and co-director of the Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Kravis Children's Hospital, Icahn School of Medicine.

Mirikizumab induction produced early clinical, endoscopic, and symptomatic improvements in children and adolescents with moderately to severely active 

, according to week 12 results from the phase 3 SHINE-2 study. The late-breaking findings were presented at the 

American College of Gastroenterology (ACG)

 2026 Annual Scientific Meeting in Nashville, Tennessee.

At week 12, 41.3% of participants aged 2 to 17 years achieved clinical remission, and 81.0% achieved clinical response.

Marla Dubinsky, MD, of the Icahn School of Medicine at Mount Sinai, told 

 the results move pediatric patients one step closer to the first approved interleukin (IL)-23p19 inhibitor for UC. Today, only infliximab, adalimumab, and ustekinumab carry pediatric UC approvals, with ustekinumab added in August 2026.

Marla Dubinsky, MD: Mirikizumab SHINE-2 Data in Pediatric Ulcerative Colitis

“Pediatric patients deserve the same sort of attention, and I would even argue a little bit more, when it comes to advanced therapies, because of the repercussions of ongoing inflammation on growth,” said Dubinsky.

Off-Label Use and the Pediatric UC Treatment Gap

Dubinsky noted ustekinumab was approved for adults with Crohn’s disease in 2016, but pediatric approval did not follow until 2026. No IL-23p19 inhibitors, sphingosine-1-phosphate receptor modulators, or Janus kinase inhibitors are approved for children with UC, leaving clinicians to prescribe off label.

She added children often present with more aggressive disease, estimating 8 in 10 pediatric patients with UC have pancolitis at diagnosis. Without pediatric trials, clinicians must estimate dosing for smaller patients, particularly those weighing less than 40 kg.

SHINE-2 Design and Weight-Based Mirikizumab Dosing

SHINE-2 enrolled 63 participants with a modified Mayo score of 5 to 9 and an endoscopic subscore of 2 or higher.

Participants received weight-based intravenous induction every 4 weeks for 3 doses (300 mg if more than 40 kg; 5 mg/kg if 40 kg or less), followed by subcutaneous maintenance every 4 weeks at 200 mg, 100 mg, or 50 mg by weight.

Investigators compared pediatric outcomes with historical results from the adult phase 3 LUCENT program.

 Dubinsky said the phase 2 SHINE-1 study established dosing, while SHINE-2 confirmed mirikizumab exposures with weight-based dosing were generally comparable across weight groups and with adults.

Week 12 Clinical, Endoscopic, and Symptomatic Outcomes in Children

At week 12, pediatric rates exceeded historical adult placebo rates for clinical remission (41.3% vs 14.6%), clinical response (81.0% vs 43.4%), endoscopic remission (25.4% vs 4.5%), and endoscopic improvement (50.8% vs 21.0%). PUCAI remission was achieved by 58.7%, and PUCAI response by 87.3%.

Symptomatic remission was observed in 38.1% of participants by week 4 and in 69.8% by week 12. Mean fecal calprotectin fell from 3734 µg/g at baseline to 1649 µg/g at week 12. By week 52, 50.0% of week 12 clinical responders were in clinical remission, comparable to the adult mirikizumab rate of 50.7%.

Through week 12, adverse events were mild or moderate, and serious adverse events occurred in 3.2% of participants.

 A single participant discontinued because of a UC flare, and no new safety concerns were identified.

Prior Advanced Therapy Exposure and Long-Term Pediatric Data

About half of SHINE-2 participants had prior exposure to advanced therapies, mirroring the refractory populations in adult trials. Dubinsky said this gives clinicians evidence to support IL-23 inhibition in children who have not responded to other agents.

“What the clinical trials do is help validate what we have been doing off label and give us the confidence that what we’re seeing in the clinic is something that’s seen in the trial, and vice versa,” said Dubinsky.

Week 52 results were presented at United European Gastroenterology Week 2026, and Eli Lilly and Company plans to submit the data to global regulators.

 Participants can continue into the SHINE-ON long-term extension.

Dubinsky MC, Bousvaros A, Griffiths AM, et al. Mirikizumab induction therapy achieves early clinical, endoscopic, and biomarker improvement in children and adolescents with moderately to severely active ulcerative colitis: week 12 results from the SHINE-2 study. Presented at: American College of Gastroenterology 2026 Annual Scientific Meeting; October 9-14, 2026; Nashville, TN.

D’Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444-2455. doi:10.1056/NEJMoa2207940

FDA approves Stelara for pediatric ulcerative colitis. US Food and Drug Administration. August 2026. Accessed October 30, 2026. 

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-stelara-pediatric-ulcerative-colitis

Lilly’s Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year phase 3 results in pediatric ulcerative colitis. News release. Eli Lilly and Company. October 19, 2026. Accessed October 30, 2026. 

https://www.biospace.com/press-releases/lillys-omvoh-mirikizumab-mrkz-meets-primary-endpoint-of-clinical-remission-and-is-the-first-il-23p19-inhibitor-to-report-one-year-phase-3-results-in-pediatric-ulcerative-colitis

Marla Dubinsky, MD, discusses phase 3 SHINE-2 data showing mirikizumab induced clinical remission in 41.3% of children with UC by week 12.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

SHINE-2 and Closing the Pediatric UC Treatment Gap, With Marla Dubinsky, MD

Clear expectations, patience before reassessing and gradual comorbidity screening are central to biologic therapy for 

moderate to severe hidradenitis suppurativa (HS)

Hsiao is a professor of dermatology at the University of Southern California and co-director of an HS specialty clinic. In this on-site interview, she spoke about her approach and other strategies for HS with 

2026 Fall Clinical Dermatology Conference

Biologic Selection and Comorbidity Screening in HS, With Jennifer Hsiao, MD

What Should Patients Expect When Starting an HS Biologic?

Hsiao tells patients that current therapies are unlikely to resolve established tunnels the way modern agents can clear psoriasis or eczema. Instead, she asks them to track drainage and pain, and whether new lesions appear less often, stay smaller, and resolve sooner. Framing responses this way helps patients recognize a partial benefit and stay on treatment.

She plans a formal reassessment 3 to 4 months after starting a biologic and explains that window at the first visit. Because options are limited, she cautioned against abandoning an agent before it has had enough time to work.

How Do Dermatologists Choose Among Approved HS Biologics?

Adalimumab, secukinumab and bimekizumab are the 3 biologics currently approved by the FDA for HS; bimekizumab was approved in November 2024.³ Hsiao weighs patient age, preferences, comorbidities and insurance coverage when choosing among them. She emphasized starting therapy promptly while a patient is willing, ideally at early moderate disease. Bridge and patient assistance programs can reduce delays in access.

Hsiao welcomed oral Janus kinase (JAK) inhibitors as a needle-free option. They may also suit patients whose disease isn’t driven by a single cytokine. In the phase 3 STOP-HS1 and STOP-HS2 trials, 40% to 42% of patients receiving povorcitinib 45 mg or 75 mg achieved HiSCR50 at week 12, compared with 29% to 30% receiving placebo. Observed HiSCR50 rates reached 57.3% to 71.4% through week 54.¹ Incyte reports that a new drug application for povorcitinib in HS is under FDA review.²

Which Comorbidities Should Be Screened in HS?

Comorbidity screening can take place over several visits, Hsiao said. The physical exam is a chance to check for acne, dissecting cellulitis of the scalp, and pilonidal disease. She advised raising tobacco cessation once rapport is established, framed as a matter of overall health rather than a cause of HS. She also recommended prioritizing questions about inflammatory bowel disease and spondyloarthritis, which affect both long-term health and the choice of biologic.

Editor's Note: This summary was edited for grammar and clarity using artificial intelligence tools. Hsiao has previously disclosed receiving consulting fees from AbbVie, Boehringer Ingelheim, Novartis, and UCB and speaker fees from AbbVie, and serving on the board of directors of the Hidradenitis Suppurativa Foundation.

Porter ML, Martorell A, Sayed CJ, et al. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. 

. 2026;32(8):3071-3081. doi:10.1038/s41591-026-04534-z.

Incyte. Incyte announces new positive 54-week late-breaking data for povorcitinib in hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting. Published March 28, 2026. Accessed October 30, 2026. 

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-new-positive-54-week-late-breaking-data

Smith T. FDA approves bimekizumab for adults with hidradenitis suppurativa. 

. Published November 20, 2024. Accessed October 30, 2026. 

https://www.hcplive.com/view/fda-approves-bimekizumab-adults-with-hidradenitis-suppurativa

Jennifer Hsiao, MD, shares how she sets expectations, selects and reassesses biologics, and screens for comorbidities in patients with hidradenitis suppurativa.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

Lawrence Eichenfield, MD, discusses phase 2 data showing nemolizumab improved itch, sleep, and quality of life in children 2 to 11 with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

What Phase 2 Nemolizumab Data Show in Children 2-11 With Atopic Dermatitis

James Chalmers, MBChB, PhD, discusses an ASPEN post hoc analysis linking sputum color to neutrophil serine protease activity at CHEST 2026.

Sputum Color Flags Severity in Bronchiectasis: James Chalmers, MBChB, PhD

Podcasts

Medcast Podcasts

NMOSD Underdiagnosed and Overlooked: A Neurologist and Pharmacist on the Path to Better Care - Podcast

Medcast Videos

NMOSD Underdiagnosed and Overlooked: A Neurologist and Pharmacist on the Path to Better Care 

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Five liver societies define ACLF as liver failure plus extrahepatic organ dysfunction or failure, with three grades and FDA-informed trial endpoints.

Hepatology

Acute-on-Chronic Liver Failure Gets Unified Global Definition, Grading

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

HCPLive Five at CHEST 2026

Nitika Chopra is a patient advocate for individuals with psoriasis.

Psoriasis advocates Nitika Chopra and Ayesha Patrick address common misconceptions, how patients can speak up, and simple tips for clinicians.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Q&A: What Should Clinicians Ask Patients About Scalp Psoriasis and Hair Care?

The FDA has pushed its decision on mitapivat for sickle cell disease to February 1, 2027, while it reviews updated safety data to decide whether a REMS is needed.

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Latest News

Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

IgAN Progression Risk: Proteinuria, eGFR Decline, and the Role of Hematuria

SHINE-2 and Closing the Pediatric UC Treatment Gap, With Marla Dubinsky, MD

Biologic Selection and Comorbidity Screening in HS, With Jennifer Hsiao, MD